Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
Comtan 200 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Brownish-orange, oval, biconvex film-coated tablet with “Comtan” engraved on one side. |
Each film-coated tablet contains 200 mg entacapone.
Excipient with known effect: Each tablet contains 1.82 mg sucrose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Entacapone |
Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors. It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. Entacapone prolongs the clinical response to levodopa. |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose Film-coating: Hypromellose |
Amber glass bottles (hydrolytic class III) with white tamper-resistant polypropylene closures containing 30, 60 or 100 tablets.
Not all pack sizes may be marketed.
Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
EU/1/98/081/001-003
Date of first authorisation: 22 September 1998
Date of latest renewal: 03 September 2008
| Drug | Countries | |
|---|---|---|
| COMTAN | Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Japan, Lithuania, Netherlands, New Zealand, Poland, Singapore, Tunisia, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
